Document Detail

Do flavonoid intakes of postmenopausal women with breast cancer vary on very low fat diets?
MedLine Citation:
PMID:  18584478     Owner:  NLM     Status:  MEDLINE    
In the Women's Intervention Nutrition Study (WINS), a very low-fat eating pattern decreased breast cancer recurrence. We assessed whether the women's flavonoid intakes varied on the very low fat diet. A total of 550 randomly selected WINS participants who had been treated with conventional therapy (surgery, chemotherapy, and/or radiation) for primary breast cancer were randomized to either a very low fat diet (15% of calories from fat, N = 218) or their usual diets (30% calories from fat, N = 332). We compared their intakes of total flavonoids and 6 flavonoid classes (isoflavones, flavones, flavanones, flavonols, flavan-3-ols, and anthocyanins) for these 2 groups using the U.S. Department of Agriculture food flavonoid database and a flavonoid dietary supplement database on three 24-h dietary recalls at baseline and 12 mo after randomization. At baseline, neither mean fat intakes (31.7% +/- 6.8 SD of calories, n = 332 in the usual diet group and 31.6% +/- 6.8 SD of calories, n = 218 in the very low fat diet group; P = NS) nor flavonoid intakes (218 +/- 283 SD mg/day, n = 332 in the usual diet group and 236 +/- 393 SD mg/day, n = 218 in the very low fat diet group; P = NS) differed. Over half of the women's flavonoid intakes were from the flavan-3-ols. After 12 months of intervention, with 39 participants lost to follow-up, dietary fat intakes were 30.7 +/- 8.4 SD calories (n = 316) among those on their usual diets but were significantly lower among those on the very low fat diet intervention: 21.4 +/- 8.3 SD calories (n = 195), P = <0.05. However, flavonoid intakes remained similar in both groups (201 +/- 252 SD mg/day, n = 316 in the usual diet group vs. 235 +/- 425 SD mg/day, n = 195 in the very low fat group; P = NS). In this random sample of WINS participants, neither total flavonoid intakes nor intakes of subclasses of flavonoids differed between those who had dramatically decreased their fat intakes and those who had not. Flavonoid intakes are therefore unlikely to account for WINS results on differences between the groups in cancer recurrence.
Johanna Dwyer; Julia Peterson; Barbara Winters; Weiqing Liu; Diane C Mitchell; Karen Atkinson
Related Documents :
18584478 - Do flavonoid intakes of postmenopausal women with breast cancer vary on very low fat di...
1845168 - Plasma pepsinogens, nutrients, and diet in areas of italy at varying gastric cancer risk.
14747688 - Telephone counseling intervention increases intakes of micronutrient- and phytochemical...
17215198 - Time-lag estimate between dietary intake and breast cancer mortality in japan.
10563878 - Influence of dietary fat and vitamin e on antioxidant status of muscles of turkey.
21343408 - Cholesterol: a novel regulatory role in myelin formation.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Nutrition and cancer     Volume:  60     ISSN:  1532-7914     ISO Abbreviation:  Nutr Cancer     Publication Date:  2008  
Date Detail:
Created Date:  2008-06-27     Completed Date:  2008-11-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905040     Medline TA:  Nutr Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  450-60     Citation Subset:  IM    
Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts 02111, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / diet therapy*
Diet, Fat-Restricted*
Dietary Supplements
Flavonoids / administration & dosage*
Middle Aged
Neoplasm Recurrence, Local / prevention & control*
Women's Health
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dietary flavonoid sources in Australian adults.
Next Document:  Orally administered isoflavones are present as glucuronides in the human prostate.